2022 Updates in Lung Cancer Treatment

2 years ago

By Dr. Kanak Parmar Texas Tech University   Perioperative systemic therapy for resectable non-small cell lung cancer Surgical resection followed…

De-escalating Therapy in Human Papillomavirus-Related Oropharyngeal Cancer

2 years ago

By Dr. Tarik Hadid Wayne State University   Human papillomavirus (HPV) is a small DS-DNA virus, and humans are the…

The CALYPSO Study Tests the Combination of MET and PD-L1 Inhibition in Patients with Advanced Papillary Renal Cancer

2 years ago

By Dr. Inas Abuali Massachusetts General Hospital   There is a paucity of available treatment options for patients with advanced…

FDA Approves an Expanded Indication of Abemaciclib with Endocrine Therapy for Early Breast Cancer

2 years ago

On March 4, 2023, the U.S. Food and Drug Administration approved expanded use of adjuvant abemaciclib with endocrine therapy for…

Interview with Dr. Chadi Nabhan

2 years ago

Dr. Dipesh Uprety interviewed Dr. Chadi Nabhan about his new book, Toxic Exposure. Watch the video to hear more about…

Multicenter Real-World Study Shows Comparable Safety and Efficacy of Ide-Cel in Patients with Relapsed/Refractory Multiple Myeloma

2 years ago

By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health   A multicenter retrospective study, which…

2023 Summit on Cancer Health Disparities (SCHD)

2 years ago

SEATTLE, WA - The Binaytara Foundation, a non-profit organization dedicated to improving healthcare in underserved communities, is proud to announce…

Hematology Cancer Consortium (HCC): Collaboration Toward Improving Care in India

2 years ago

By Dr. Chepsy Philip Believers Church Medical College Hospital   Care of hematological cancers in India and other low- and…

KRD Maintenance: Another Alternative for Newly Diagnosed Multiple Myeloma?

2 years ago

By Dr. Harsh Parmar Hackensack Meridian Health   In an unplanned interim analysis of an international phase-III trial (ATLAS) by…

FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer

2 years ago

On February 9th, 2023, the U.S. Food and Drug Administration approved dostarlimab-gxly for adult patients with recurrent or advanced endometrial…